Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer - PubMed (original) (raw)
Review
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al. Nat Clin Pract Oncol. 2006 May.
Abstract
Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of invasive breast cancers. The majority of patients with metastatic breast cancer who initially respond to trastuzumab, however, demonstrate disease progression within 1 year of treatment initiation. Preclinical studies have indicated several molecular mechanisms that could contribute to the development of trastuzumab resistance. Increased signaling via the phosphatidylinositol 3-kinase/Akt pathway could contribute to trastuzumab resistance because of activation of multiple receptor pathways that include HER2-related receptors or non-HER receptors such as the insulin-like growth factor 1 receptor, which appears to be involved in a cross-talk with HER2 in resistant cells. Additionally, loss of function of the tumor suppressor PTEN gene, the negative regulator of Akt, results in heightened Akt signaling that leads to decreased sensitivity to trastuzumab. Decreased interaction between trastuzumab and its target receptor HER2, which is due to steric hindrance of HER2 by cell surface proteins such as mucin-4 (MUC4), may block the inhibitory actions of trastuzumab. Novel therapies targeted against these aberrant molecular pathways offer hope that the effectiveness and duration of response to trastuzumab can be greatly improved.
Similar articles
- Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Tseng PH, et al. Mol Pharmacol. 2006 Nov;70(5):1534-41. doi: 10.1124/mol.106.023911. Epub 2006 Aug 3. Mol Pharmacol. 2006. PMID: 16887935 - Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R, O'Regan RM. Nahta R, et al. Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Clin Breast Cancer. 2010. PMID: 21115425 Review. - Progression and treatment of HER2-positive breast cancer.
Davoli A, Hocevar BA, Brown TL. Davoli A, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20. Cancer Chemother Pharmacol. 2010. PMID: 20087739 - Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL, Blackwell KL. Spector NL, et al. J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884552 Review. - HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
Cited by
- Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. Wang YC, et al. Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28. Breast Cancer Res. 2011. PMID: 22123186 Free PMC article. - PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer.
Scerri J, Scerri C, Schäfer-Ruoff F, Fink S, Templin M, Grech G. Scerri J, et al. Front Endocrinol (Lausanne). 2022 Oct 18;13:1010092. doi: 10.3389/fendo.2022.1010092. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36329884 Free PMC article. - Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Liu S, Wang H, Zhang L, Tang C, Jones L, Ye H, Ban L, Wang A, Liu Z, Lou F, Zhang D, Sun H, Dong H, Zhang G, Dong Z, Guo B, Yan H, Yan C, Wang L, Su Z, Li Y, Huang XF, Chen SY, Zhou T. Liu S, et al. Hum Genomics. 2015 Feb 8;9(1):2. doi: 10.1186/s40246-015-0024-4. Hum Genomics. 2015. PMID: 25757876 Free PMC article. - Targeted therapies for lung cancer: clinical experience and novel agents.
Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD. Larsen JE, et al. Cancer J. 2011 Nov-Dec;17(6):512-27. doi: 10.1097/PPO.0b013e31823e701a. Cancer J. 2011. PMID: 22157296 Free PMC article. Review. - Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.
Peddi PF, Hurvitz SA. Peddi PF, et al. Future Oncol. 2013 Mar;9(3):319-26. doi: 10.2217/fon.13.7. Future Oncol. 2013. PMID: 23469968 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous